KRBP vs. ADXS, PBLA, BPTH, VAXX, ASLN, SLRX, CWBR, BPTSY, PTEIQ, and EVFM
Should you be buying Kiromic BioPharma stock or one of its competitors? The main competitors of Kiromic BioPharma include Ayala Pharmaceuticals (ADXS), Panbela Therapeutics (PBLA), Bio-Path (BPTH), Vaxxinity (VAXX), ASLAN Pharmaceuticals (ASLN), Salarius Pharmaceuticals (SLRX), CohBar (CWBR), Biophytis (BPTSY), PolarityTE (PTEIQ), and Evofem Biosciences (EVFM). These companies are all part of the "pharmaceutical products" industry.
Kiromic BioPharma vs.
Kiromic BioPharma (NASDAQ:KRBP) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, community ranking, analyst recommendations, valuation and risk.
Kiromic BioPharma has higher earnings, but lower revenue than Ayala Pharmaceuticals. Ayala Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiromic BioPharma, indicating that it is currently the more affordable of the two stocks.
Kiromic BioPharma received 1 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 50.00% of users gave Kiromic BioPharma an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote.
In the previous week, Ayala Pharmaceuticals had 1 more articles in the media than Kiromic BioPharma. MarketBeat recorded 1 mentions for Ayala Pharmaceuticals and 0 mentions for Kiromic BioPharma. Kiromic BioPharma's average media sentiment score of 0.00 equaled Ayala Pharmaceuticals'average media sentiment score.
Kiromic BioPharma has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.
10.9% of Kiromic BioPharma shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 20.6% of Kiromic BioPharma shares are held by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Kiromic BioPharma beats Ayala Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
Get Kiromic BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRBP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiromic BioPharma Competitors List
Related Companies and Tools
This page (NASDAQ:KRBP) was last updated on 4/20/2025 by MarketBeat.com Staff
Buy KRBP Stock Free KRBP Stock Alerts